Northern Trust Corp Tenaya Therapeutics, Inc. Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 397,661 shares of TNYA stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

397,661

Previous 389,682 2.05%

Holding current value

$1.67 Million

Previous $1.26 Million 64.74%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.88 - $6.8 $22,979 - $54,257	7,979 Added 2.05%	397,661 $2.08 Million
Q4 2023 Feb 13, 2024	SELL	$1.73 - $3.39 $68,423 - $134,077	-39,551 Reduced 9.21%	389,682 $1.26 Million
Q3 2023 Nov 13, 2023	BUY	$2.55 - $5.65 $29,643 - $65,681	11,625 Added 2.78%	429,233 $1.09 Million
Q2 2023 Aug 11, 2023	BUY	$2.64 - $7.64 $183,912 - $532,232	69,664 Added 20.02%	417,608 $2.45 Million
Q1 2023 May 15, 2023	BUY	$1.92 - $3.59 $239,677 - $448,146	124,832 Added 55.95%	347,944 $991,000

Q4 2022 Feb 13, 2023	SELL	$1.68 - $3.19 $12,947 - $24,585	-7,707 Reduced 3.34%	223,112 $448,000
Q3 2022 Nov 14, 2022	BUY	$2.9 - $5.88 $25,241 - $51,179	8,704 Added 3.92%	230,819 $670,000
Q2 2022 Aug 12, 2022	SELL	$5.01 - $14.12 $46,813 - $131,937	-9,344 Reduced 4.04%	222,115 $1.25 Million
Q1 2022 May 13, 2022	BUY	$9.41 - $19.3 $861,824 - $1.77 Million	91,586 Added 65.48%	231,459 $2.73 Million
Q4 2021 Feb 08, 2022	BUY	$18.41 - $29.58 $305,293 - $490,525	16,583 Added 13.45%	139,873 $2.65 Million
Q3 2021 Nov 15, 2021	BUY	$15.35 - $26.66 $1.89 Million - $3.29 Million	123,290 New	123,290 $2.55 Million

Others Institutions Holding TNYA

# of Institutions

Shares Held

47.2M

Call Options Held

35.8K

Put Options Held

1.1K

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $174M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Tenaya Therapeutics, Inc. Transaction History